76%
of retail accounts lose money when trading CFDs with this provider.
Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
76%
of retail investor accounts lose money when trading CFDs with this provider.
You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money.
76%
of retail accounts lose money when trading CFDs with this provider.
Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
76%
of retail investor accounts lose money when trading CFDs with this provider.
You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money.
English (International)
SIGA Technologies Inc
Closed
SectorHealthcare
6.54 1.4
Overview
Share price change
24h
Min
6.38
Max
6.59
Income | -46M -408K |
|---|---|
Sales | -74M 7M |
P/E Sector Avg | 9.239 50.291 |
EPS | -0.006 |
Profit margin | -5.798 |
Employees | 46 |
EBITDA | -59M -2.1M |
Next Earnings | 31 Jul 2025 |
|---|
Market Cap | 40M 442M |
|---|---|
Previous open | 5.14 |
Previous close | 6.54 |
News Sentiment
By Acuity
34%
66%
97 / 380 Healthcare
Technical Score
By Trading Central
Confidence
Very Strong Bearish Evidence
SIGA Technologies Inc Chart
Past performance is not a reliable indicator of future results.
Related News
Peer Comparison
Price change
SIGA Technologies Inc Forecast
Sentiment
By Acuity
97 / 380 Healthcare
News Sentiment
Bullish Evidence
Volatility
Below average
News Volume (RCV)
Below average
Financials
Selling and administration expenses
Operating expenses
Pre-tax profit
Sales
Cost of sales
Gross profit on sales
Interest expense on debt
EBITDA
Operating profit
$
About SIGA Technologies Inc
SIGA Technologies, Inc., a commercial-stage pharmaceutical company, focuses on the health security related markets in the United States. Its lead product is TPOXX, an oral formulation antiviral drug for the treatment of human smallpox disease caused by variola virus. The company was incorporated in 1995 and is headquartered in New York, New York.
